• Price Band fixed at ₹1,008 to ₹1,062 per Equity Share of face value of ₹10 each of Corona Remedies Limited (“Equity Shares”);
  • Bid /Offer will open on Monday, December 08, 2025 and close on Wednesday, December 10, 2025. The Anchor Investor Bidding Date is Friday, December 05, 2025;
  • Bids can be made for a minimum of 14 Equity Shares and in multiples of 14 Equity Shares thereafter;
  • A discount of ₹54 per Equity share is being offered to Eligible Employees bidding in the Employee Reservation Portion.
  • Red Herring Prospectus (“RHP”)  link:  https://live.jmfl.com/od/UploadedFiles/D85CD184-902B-431E-8620-18ABC2F68BE8.pdf

Mumbai :  Corona Remedies Limited  (CRL) will open the Bid / Offer in relation to its initial public offering (IPO) of the Equity Shares on Monday, December 08, 2025. The Bid/Offer will close on Wednesday, December 10, 2025. The Price Band has been fixed at ₹1,008 to ₹1,062 per Equity Share. JM Financial Limited, IIFL Capital Services Limited and Kotak Mahindra Capital Company Limited are the Book Running Lead Managersto the Offer.

The Anchor Investor Bidding Date shall be on Friday, December 05, 2025. Bids can be made for a minimum of 14 Equity Shares and in multiples of 14 Equity Shares thereafter. The Offer comprises an offer for sale (OFS) of Up to [●] Equity Shares of face value of ₹10 each aggregating up to ₹6,553.71 million.

The OFS comprises of up to [●] Equity Shares of face value of ₹10 each aggregating up to ₹1,298.41 million by  Dr. Kirtikumar Laxmidas  Mehta (Promoter Selling Shareholder); Up to [●] Equity Shares of face value of ₹10 each aggregating up to ₹766.07 million by Minaxi Kirtikumar Mehta (Promoting Group Selling Shareholder); Up to [●] Equity Shares of face value of ₹10 each aggregating up to ₹103.87 million by Dipabahen Niravkumar Mehta (Promoting Group Selling Shareholder); Up to [●] Equity Shares of face value of ₹10 each aggregating up to ₹103.87 million by Brinda Ankur Mehta (Promoting Group Selling Shareholder) & Up to [●] Equity Shares of face value of ₹10 each aggregating up to ₹ 4,046.00 million by Sepia Investments Limited (Investor Selling Shareholder) ; Up to [●] Equity Shares of face value of ₹10 each aggregating up to ₹151.25 million by Anchor Partners (Investor Selling Shareholder); Up to [●] Equity Shares of face value of ₹10 each aggregating up to ₹84.24 million by Sage Investment Trust (Investor Selling Shareholder).

A discount of ₹ 54 per Equity Share is being offered to Eligible Employees bidding in the Employee Reservation Portion.

The Equity Shares, offered through the Red Herring Prospectus of the Company (“RHP”) are proposed to be listed on National Stock Exchange of India Limited (“NSE”) and BSE Limited (“BSE” and together with NSE, the “Stock Exchanges”).

Corona Remedies is an India-focused branded pharmaceutical formulation company engaged in developing, manufacturing and marketing products in women’s healthcare, cardio-diabeto, pain management, urology and other therapeutic areas. The company has a diversified product portfolio comprising 71 brands catering to a range of therapeutic areas as of June 30, 2025.

According to the CRISIL Intelligence Report, Corona Remedies is the fastest growing company among the top 30 companies in the Indian Pharmaceutical Market (“IPM”) in terms of domestic sales in the IPM, between MAT June 2024 and MAT June 2025. *MAT is the moving annual total. Corona Remedies was the second fastest growing company among the top 30 companies in the IPM in terms of domestic sales between MAT June 2022 and MAT June 2025.